Meeting
2015 ASCO Annual Meeting
Impact of systemic therapy on the outcomes of patients with metastatic breast cancer to brain: MD Anderson Cancer Center (MDACC) experience 1999-2012.
Authors
Diogo Bugano Diniz Gomes
The University of Texas MD Anderson Cancer Center, Houston, TX
Diogo Bugano Diniz Gomes , Rita Elias Deeba , Dima Suki , Vicente Valero , Stacy L. Moulder , Banu Arun , Kimberly Higginbotham Koenig , Eric A Strom , Limin Hsu , Raymond Sawaya , Debu Tripathy , Nuhad K. Ibrahim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 33, 2015 (suppl; abstr 1046)
DOI
10.1200/jco.2015.33.15_suppl.1046
Abstract #
1046
Poster Bd #
160
Abstract Disclosures
Similar Posters
Poster
2014 Breast Cancer Symposium
Impact of chemotherapy and radiation therapy on local control and survival of metastatic breast cancer to the brain: Single-institution review of 792 cases.
First Author: Diogo Bugano Diniz Gomes
Poster
2018 Gastrointestinal Cancers Symposium
Outcomes for advanced HER2-positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.
First Author: Charles Henry Lim
Poster
2023 ASCO Annual Meeting
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial.
First Author: Min Yan
Poster
2018 ASCO Annual Meeting
Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.
First Author: Ander Urruticoechea